Pharmacokinetics and local tolerance of cefovecin sodium after intra-articular administration in horses.

The study looks into the effects and effectiveness of cefovecin sodium as a new treatment option for septic arthritis in horses. It finds that the drug offers a promising pharmacokinetic performance and has good tolerance locally.

Objective and Methodology

• The overarching purpose of this research is finding alternative treatments for septic arthritis in horses. The investigation focused on cefovecin sodium’s pharmacokinetics—a drug’s absorption, distribution, metabolism, and excretion over time—and its local tolerance when administered intra-articularly or within the joint.
• The experiment involved a single 240mg dose of cefovecin sodium (commercially known as Convenia) injected into the radiocarpal (wrist) joint of six healthy adult horses.
• Subsequent concentrations of the drug in plasma and synovial fluid—the lubricating fluid in joints—were determined using a method called high-performance liquid chromatography (HPLC), an analytical chemistry technique used to identify, quantify, and purify individual components of a mixture.

Indicators and Observations

• The study also examined various joint physiopathological parameters to understand local tolerance. These included the pH levels, cellular concentration, and protein concentration in the synovial fluid.
• There were notable increases in protein concentrations at the 5-minute mark and cellular concentration at 30 minutes after the cefovecin sodium administration. However, no clinically relevant joint damage was observed.
• The study found the duration of cefovecin being above the Minimal Inhibitory Concentration (MIC), the lowest concentration of a drug that prevents bacterial growth, was approximately 28.80 hours ± 2.58 hours in the joint and around 16.00 hours ± 2.86 hours in the plasma.

Conclusion and Future Scope

• The findings from this study indicate that cefovecin sodium’s intra-articular administration in horses could be contemplated for future treatment of septic arthritis. This proposition is based on the drug’s commendable pharmacokinetic behavior and its subtle impact on the joint’s physiological parameters.